GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price, Forecast & Analysis
USA - NYSE:DNA - US37611X2099 - Common Stock
DNA Key Statistics, Chart & Performance
The current stock price of DNA is 11.3 USD. In the past month the price decreased by -25.85%. In the past year, price increased by 33.1%.
DNA Latest News, Press Relases and Analysis
DNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.27 | 213.72B | ||
| DHR | DANAHER CORP | 27.32 | 150.85B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 156.65 | 47.53B | ||
| A | AGILENT TECHNOLOGIES INC | 27.06 | 41.81B | ||
| IQV | IQVIA HOLDINGS INC | 18.13 | 35.85B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.2 | 29.66B | ||
| WAT | WATERS CORP | 29.23 | 22.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.94 | 19.80B | ||
| ILMN | ILLUMINA INC | 27.78 | 18.61B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.41 | 16.63B | ||
| TEM | TEMPUS AI INC | N/A | 12.52B | ||
| ICLR | ICON PLC | 12.13 | 12.44B |
Related stock screener links
About DNA
Company Profile
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Company Info
GINKGO BIOWORKS HOLDINGS INC
27 Drydock Avenue, 8th Floor
Boston MASSACHUSETTS US
CEO: Harry E. Sloan
Employees: 834
Phone: 18774425362
GINKGO BIOWORKS HOLDINGS INC / DNA FAQ
What does GINKGO BIOWORKS HOLDINGS INC do?
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
What is the stock price of GINKGO BIOWORKS HOLDINGS INC today?
The current stock price of DNA is 11.3 USD. The price decreased by -2.5% in the last trading session.
Does GINKGO BIOWORKS HOLDINGS INC pay dividends?
DNA does not pay a dividend.
What is the ChartMill rating of GINKGO BIOWORKS HOLDINGS INC stock?
DNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists DNA stock?
DNA stock is listed on the New York Stock Exchange, Inc. exchange.
Can you provide the PE ratio for DNA stock?
GINKGO BIOWORKS HOLDINGS INC (DNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.72).
DNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DNA. When comparing the yearly performance of all stocks, DNA is one of the better performing stocks in the market, outperforming 77.45% of all stocks.
DNA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DNA. DNA has a great financial health rating, but its profitability evaluates not so good.
DNA Financial Highlights
Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -5.72. The EPS increased by 65.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.6% | ||
| ROE | -51.42% | ||
| Debt/Equity | 0 |
DNA Forecast & Estimates
11 analysts have analysed DNA and the average price target is 12.24 USD. This implies a price increase of 8.32% is expected in the next year compared to the current price of 11.3.
For the next year, analysts expect an EPS growth of 40.65% and a revenue growth -22.25% for DNA